Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

October 1, 2020

Study Completion Date

January 13, 2021

Conditions
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical CarcinomaStage IV Cervical Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
DRUG

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (22)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Hospital and Clinics, Madison

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91105

Keck Medical Center of USC Pasadena, Pasadena

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter